{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T08:37:50Z","timestamp":1792744670854,"version":"4.5.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"DOI":"10.1007\/s40259-026-00814-9","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T07:42:17Z","timestamp":1792741337000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["IL-6 Blockade for Antibody-Mediated Transplant Rejection: What Does the Evidence Say?"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1297-0675","authenticated-orcid":false,"given":"Mehmet","family":"Kanbay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sidar","family":"Copur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Can","family":"Altunbulakli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeynep B.","family":"Eren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Gulmaliyev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nur I.","family":"Genc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caner","family":"S\u00fcsal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Covic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmut","family":"Altindal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,23]]},"reference":[{"issue":"5","key":"814_CR1","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1097\/TP.0000000000004822","volume":"108","author":"M Berger","year":"2024","unstructured":"Berger M, Baliker M, Van Gelder T, B\u00f6hmig GA, Mannon RB, Kumar D, et al. Chronic active antibody-mediated rejection: opportunity to determine the role of interleukin-6 blockade. Transplantation. 2024;108(5):1109\u201314.","journal-title":"Transplantation"},{"issue":"2","key":"814_CR2","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1111\/ajt.14625","volume":"18","author":"M Haas","year":"2017","unstructured":"Haas M, Loupy A, Lefaucheur C, Roufosse C, Glotz D, Seron D, et al. The Banff 2017 Kidney Meeting Report: revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials. Am J Transplant. 2017;18(2):293\u2013307.","journal-title":"Am J Transplant"},{"issue":"5","key":"814_CR3","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1097\/TP.0000000000003095","volume":"104","author":"CA Schinstock","year":"2019","unstructured":"Schinstock CA, Mannon RB, Budde K, Chong AS, Haas M, Knechtle S, et al. Recommended treatment for antibody-mediated rejection after kidney transplantation: the 2019 Expert Consensus from the Transplantion Society Working Group. Transplantation. 2019;104(5):911\u201322.","journal-title":"Transplantation"},{"issue":"4","key":"814_CR4","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1111\/ajt.14520","volume":"18","author":"F Moreso","year":"2018","unstructured":"Moreso F, Crespo M, Ruiz JC, Torres A, Gutierrez-Dalmau A, Osuna A, et al. Treatment of chronic antibody mediated rejection with intravenous immunoglobulins and rituximab: a multicenter, prospective, randomized, double-blind clinical trial. Am J Transplant. 2018;18(4):927\u201335.","journal-title":"Am J Transplant"},{"issue":"6","key":"814_CR5","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.4049\/jimmunol.1401190","volume":"194","author":"KM Chavele","year":"2015","unstructured":"Chavele KM, Merry E, Ehrenstein MR. Cutting edge: circulating plasmablasts induce the differentiation of human T follicular helper cells via IL-6 production. J Immunol. 2015;194(6):2482\u20135.","journal-title":"J Immunol"},{"issue":"2","key":"814_CR6","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1097\/BOR.0000000000000255","volume":"28","author":"X Liu","year":"2016","unstructured":"Liu X, Jones GW, Choy EH, Jones SA. The biology behind interleukin-6 targeted interventions. Curr Opin Rheumatol. 2016;28(2):152\u201360.","journal-title":"Curr Opin Rheumatol"},{"issue":"5","key":"814_CR7","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/ni.3153","volume":"16","author":"CA Hunter","year":"2015","unstructured":"Hunter CA, Jones SA. IL-6 as a keystone cytokine in health and disease. Nat Immunol. 2015;16(5):448\u201357.","journal-title":"Nat Immunol"},{"issue":"6092","key":"814_CR8","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/324073a0","volume":"324","author":"T Hirano","year":"1986","unstructured":"Hirano T, Yasukawa K, Harada H, Taga T, Watanabe Y, Matsuda T, et al. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature. 1986;324(6092):73\u20136.","journal-title":"Nature"},{"issue":"10","key":"814_CR9","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1084\/jem.188.10.1895","volume":"188","author":"M Kopf","year":"1998","unstructured":"Kopf M, Herren S, Wiles MV, Pepys MB, Kosco-Vilbois MH. Interleukin 6 influences germinal center development and antibody production via a contribution of C3 complement component. J Exp Med. 1998;188(10):1895\u2013906.","journal-title":"J Exp Med"},{"issue":"3","key":"814_CR10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0017739","volume":"6","author":"D Eto","year":"2011","unstructured":"Eto D, Lao C, DiToro D, Barnett B, Escobar TC, Kageyama R, et al. IL-21 and IL-6 are critical for different aspects of B cell immunity and redundantly induce optimal follicular helper CD4 T cell (Tfh) differentiation. PLoS ONE. 2011;6(3):e17739.","journal-title":"PLoS ONE"},{"issue":"12","key":"814_CR11","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1097\/TP.0000000000003249","volume":"104","author":"SC Jordan","year":"2020","unstructured":"Jordan SC, Ammerman N, Choi J, Kumar S, Huang E, Toyoda M, et al. Interleukin-6: an important mediator of allograft injury. Transplantation. 2020;104(12):2497\u2013506.","journal-title":"Transplantation"},{"issue":"2","key":"814_CR12","doi-asserted-by":"publisher","first-page":"F276","DOI":"10.1152\/ajprenal.00258.2011","volume":"302","author":"H Wang","year":"2012","unstructured":"Wang H, Guan Q, Lan Z, Li S, Ge W, Chen H, et al. Prolonged renal allograft survival by donor interleukin-6 deficiency: association with decreased alloantibodies and increased intragraft T regulatory cells. Am J Physiol Renal Physiol. 2012;302(2):F276\u201383.","journal-title":"Am J Physiol Renal Physiol"},{"issue":"3","key":"814_CR13","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s40472-021-00331-4","volume":"8","author":"CL Miller","year":"2021","unstructured":"Miller CL, Madsen JC. IL-6 directed therapy in transplantation. Curr Transplant Rep. 2021;8(3):191\u2013204.","journal-title":"Curr Transplant Rep"},{"issue":"1","key":"814_CR14","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1111\/ajt.16709","volume":"22","author":"T Jouve","year":"2022","unstructured":"Jouve T, Laheurte C, Noble J, Weinhard J, Daligault M, Renaudin A, et al. Immune responses following tocilizumab therapy to desensitize HLA-sensitized kidney transplant candidates. Am J Transplant. 2022;22(1):71\u201384.","journal-title":"Am J Transplant"},{"issue":"2","key":"814_CR15","first-page":"314","volume":"71","author":"MH Van Oers","year":"1988","unstructured":"Van Oers MH, Van der Heyden AA, Aarden LA. Interleukin 6 (IL-6) in serum and urine of renal transplant recipients. Clin Exp Immunol. 1988;71(2):314\u20139.","journal-title":"Clin Exp Immunol"},{"issue":"7090","key":"814_CR16","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/nature04753","volume":"441","author":"E Bettelli","year":"2006","unstructured":"Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006;441(7090):235\u20138.","journal-title":"Nature"},{"issue":"5","key":"814_CR17","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfaf108","volume":"18","author":"M Kanbay","year":"2025","unstructured":"Kanbay M, Mizrak B, Copur S, Alper EN, Akgul S, Ortiz A, et al. Targeting IL-6 in antibody-mediated kidney transplant rejection. Clin Kidney J. 2025;18(5):sfaf108.","journal-title":"Clin Kidney J"},{"issue":"10","key":"814_CR18","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1038\/s41577-023-00856-y","volume":"23","author":"S Rose-John","year":"2023","unstructured":"Rose-John S, Jenkins BJ, Garbers C, Moll JM, Scheller J. Targeting IL-6 trans-signalling: past, present and future prospects. Nat Rev Immunol. 2023;23(10):666\u201381.","journal-title":"Nat Rev Immunol"},{"issue":"11","key":"814_CR19","doi-asserted-by":"publisher","first-page":"2752","DOI":"10.1172\/JCI119821","volume":"100","author":"V Modur","year":"1997","unstructured":"Modur V, Li Y, Zimmerman GA, Prescott SM, McIntyre TM. Retrograde inflammatory signaling from neutrophils to endothelial cells by soluble interleukin-6 receptor alpha. J Clin Invest. 1997;100(11):2752\u20136.","journal-title":"J Clin Invest"},{"issue":"3","key":"814_CR20","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.14851","volume":"37","author":"J Lion","year":"2023","unstructured":"Lion J, Maitre ML, de Truchis C, Taupin J-L, Poussin K, Haziot A, et al. Restriction of interleukin-6 alters endothelial cell immunogenicity in an allogenic environment. Clin Transplant. 2023;37(3):e14851.","journal-title":"Clin Transplant"},{"key":"814_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.778359","volume":"12","author":"M Ma","year":"2021","unstructured":"Ma M, Sun Q, Li X, Deng G, Zhang Y, Yang Z, et al. Blockade of IL-6\/IL-6R signaling attenuates acute antibody-mediated rejection in a mouse cardiac transplantation model. Front Immunol. 2021;12:778359.","journal-title":"Front Immunol"},{"issue":"9","key":"814_CR22","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1111\/ajt.12803","volume":"14","author":"D Toki","year":"2014","unstructured":"Toki D, Zhang W, Hor KLM, Liuwantara D, Alexander SI, Yi Z, et al. The role of macrophages in the development of human renal allograft fibrosis in the first year after transplantation. Am J Transplant. 2014;14(9):2126\u201336.","journal-title":"Am J Transplant"},{"issue":"11","key":"814_CR23","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.1097\/TP.0000000000000741","volume":"99","author":"AA Vo","year":"2015","unstructured":"Vo AA, Choi J, Kim I, Louie S, Cisneros K, Kahwaji J, et al. A phase I\/II trial of the interleukin-6 receptor-specific humanized monoclonal (tocilizumab) + intravenous immunoglobulin in difficult to desensitize patients. Transplantation. 2015;99(11):2356\u201363.","journal-title":"Transplantation"},{"issue":"2","key":"814_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12020424","volume":"12","author":"T Jouve","year":"2023","unstructured":"Jouve T, Daligault M, Noble J, Terrec F, Imerzoukene F, Dard C, et al. Tocilizumab evaluation in HLA-desensitization before kidney transplantation as an add-on therapy to apheresis: the TETRA study. J Clin Med. 2023;12(2):424.","journal-title":"J Clin Med"},{"issue":"9","key":"814_CR25","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1111\/ajt.14228","volume":"17","author":"J Choi","year":"2017","unstructured":"Choi J, Aubert O, Vo A, Loupy A, Haas M, Puliyanda D, et al. Assessment of tocilizumab (anti-interleukin-6 receptor monoclonal) as a potential treatment for chronic antibody-mediated rejection and transplant glomerulopathy in HLA-sensitized renal allograft recipients. Am J Transplant. 2017;17(9):2381\u20139.","journal-title":"Am J Transplant"},{"issue":"8","key":"814_CR26","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.13908","volume":"34","author":"A Lavacca","year":"2020","unstructured":"Lavacca A, Presta R, Gai C, Mella A, Gallo E, Camussi G, et al. Early effects of first-line treatment with anti-interleukin-6 receptor antibody tocilizumab for chronic active antibody-mediated rejection in kidney transplantation. Clin Transplant. 2020;34(8):e13908.","journal-title":"Clin Transplant"},{"issue":"4","key":"814_CR27","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1111\/ajt.16391","volume":"21","author":"M Massat","year":"2021","unstructured":"Massat M, Congy-Jolivet N, Hebral A-L, Esposito L, Marion O, Delas A, et al. Do anti-IL-6R blockers have a beneficial effect in the treatment of antibody-mediated rejection resistant to standard therapy after kidney transplantation? Am J Transplant. 2021;21(4):1641\u20139.","journal-title":"Am J Transplant"},{"key":"814_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.790547","volume":"8","author":"J Noble","year":"2021","unstructured":"Noble J, Giovannini D, Laamech R, Imerzoukene F, Janbon B, Marchesi L, et al. Tocilizumab in the treatment of chronic antibody-mediated rejection post kidney transplantation: clinical and histological monitoring. Front Med. 2021;8:790547.","journal-title":"Front Med"},{"key":"814_CR29","doi-asserted-by":"publisher","first-page":"663","DOI":"10.34067\/KID.0000182019","volume":"1","author":"D Kumar","year":"2020","unstructured":"Kumar D, Yakubu I, Safavi F, Levy M, Moinuddin I, Kimball P, et al. Lack of histological and molecular signature response to tocilizumab in kidney transplants with chronic active antibody mediated rejection: a case series. Kidney360. 2020;1:663\u201370.","journal-title":"Kidney360"},{"issue":"8","key":"814_CR30","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.14734","volume":"36","author":"M Pearl","year":"2022","unstructured":"Pearl M, Weng PL, Chen L, Dokras A, Pizzo H, Garrison J, et al. Long term tolerability and clinical outcomes associated with tocilizumab in the treatment of refractory antibody mediated rejection (AMR) in pediatric renal transplant recipients. Clin Transplant. 2022;36(8):e14734.","journal-title":"Clin Transplant"},{"key":"814_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/ti.2025.14502","volume":"38","author":"J Noble","year":"2025","unstructured":"Noble J, Comai G, Corredetti V, Laamech R, Dard C, Jouve T, et al. Tocilizumab-based treatment of microvascular inflammation in kidney transplant recipients: a retrospective study. Transpl Int. 2025;38:14502.","journal-title":"Transpl Int"},{"issue":"4","key":"814_CR32","doi-asserted-by":"publisher","first-page":"e543","DOI":"10.1097\/TXD.0000000000000988","volume":"6","author":"AA Pottebaum","year":"2020","unstructured":"Pottebaum AA, Venkatachalam K, Liu C, Brennan DC, Murad H, Malone AF, et al. Efficacy and safety of tocilizumab in the treatment of acute active antibody-mediated rejection in kidney transplant recipients. Transplant Direct. 2020;6(4):e543.","journal-title":"Transplant Direct"},{"issue":"1","key":"814_CR33","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.14853","volume":"37","author":"P Khairallah","year":"2023","unstructured":"Khairallah P, Robbins-Juarez S, Patel S, Shah V, Toma K, Fernandez H, et al. Tocilizumab for the treatment of chronic antibody mediated rejection in kidney transplant recipients. Clin Transplant. 2023;37(1):e14853.","journal-title":"Clin Transplant"},{"issue":"8","key":"814_CR34","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1016\/j.ajt.2026.04.018","volume":"26","author":"A Djamali","year":"2026","unstructured":"Djamali A, B\u00f6hmig GA, Mannon RB, Chadban S, Kumar D, van Gelder T, et al. Clazakizumab in the treatment of chronic active antibody-mediated kidney transplant rejection: results from the IMAGINE phase 3, randomized, double-blind, placebo-controlled study. Am J Transplant. 2026;26(8):1864\u201378.","journal-title":"Am J Transplant"},{"issue":"3","key":"814_CR35","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1681\/ASN.2020071106","volume":"32","author":"K Doberer","year":"2021","unstructured":"Doberer K, Duerr M, Halloran PF, Eskandary F, Budde K, Regele H, et al. A randomized clinical trial of anti-IL-6 antibody clazakizumab in late antibody-mediated kidney transplant rejection. J Am Soc Nephrol. 2021;32(3):708\u201322.","journal-title":"J Am Soc Nephrol"},{"issue":"Suppl. 4","key":"814_CR36","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/ajt.17207","volume":"22","author":"SC Jordan","year":"2022","unstructured":"Jordan SC, Ammerman N, Huang E, Vo A. Importance of IL-6 inhibition in prevention and treatment of antibody-mediated rejection in kidney allografts. Am J Transplant. 2022;22(Suppl. 4):28\u201337.","journal-title":"Am J Transplant"},{"issue":"4","key":"814_CR37","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1111\/ajt.16926","volume":"22","author":"AA Vo","year":"2022","unstructured":"Vo AA, Huang E, Ammerman N, Toyoda M, Ge S, Haas M, et al. Clazakizumab for desensitization in highly sensitized patients awaiting transplantation. Am J Transplant. 2022;22(4):1133\u201344.","journal-title":"Am J Transplant"},{"issue":"12","key":"814_CR38","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/j.intimp.2005.05.010","volume":"5","author":"M Mihara","year":"2005","unstructured":"Mihara M, Kasutani K, Okazaki M, Nakamura A, Kawai S, Sugimoto M, et al. Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. Int Immunopharmacol. 2005;5(12):1731\u201340.","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"814_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-022-06897-3","volume":"23","author":"PW Nickerson","year":"2022","unstructured":"Nickerson PW, B\u00f6hmig GA, Chadban S, Kumar D, Mannon RB, van Gelder T, et al. Clazakizumab for the treatment of chronic active antibody-mediated rejection (AMR) in kidney transplant recipients: phase 3 IMAGINE study rationale and design. Trials. 2022;23(1):1042.","journal-title":"Trials"},{"issue":"5","key":"814_CR40","doi-asserted-by":"publisher","first-page":"e690","DOI":"10.1097\/TXD.0000000000001139","volume":"7","author":"M Daligault","year":"2021","unstructured":"Daligault M, Bardy B, Noble J, Bourdin A, Masson D, Naciri Bennani H, et al. Marginal impact of tocilizumab monotherapy on anti-HLA alloantibodies in highly sensitized kidney transplant candidates. Transplant Direct. 2021;7(5):e690.","journal-title":"Transplant Direct"},{"issue":"11","key":"814_CR41","doi-asserted-by":"publisher","first-page":"4027","DOI":"10.1016\/j.ekir.2025.08.027","volume":"10","author":"R Zhang","year":"2025","unstructured":"Zhang R, Lee CYC, Schatzl M, Budde K, Halleck F, Jilma B, et al. The effects of clazakizumab on peripheral blood and kidney transcriptomes in patients with late antibody-mediated rejection. Kidney Int Rep. 2025;10(11):4027\u201340.","journal-title":"Kidney Int Rep"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-026-00814-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-026-00814-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-026-00814-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T07:42:18Z","timestamp":1792741338000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-026-00814-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,23]]},"references-count":41,"alternative-id":["814"],"URL":"https:\/\/doi.org\/10.1007\/s40259-026-00814-9","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,23]]},"assertion":[{"value":"24 September 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"No funding was received for the preparation of this article.","order":1,"name":"Ethics","label":"Funding","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Mehmet Kanbay, Sidar Copur, Can Altunbulakli, Zeynep B. Eren, Ibrahim Gulmaliyev, Nur I. Genc, Caner S\u00fcsal, Adrian Covic, and Mahmut Altindal have no conflicts of interest that are directly relevant to the content of this article.","order":2,"name":"Ethics","label":"Conflicts of Interest\/Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable, this article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable, no new data are generated in this article.","order":6,"name":"Ethics","label":"Availability of Data and Material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":7,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MK: methodology, formal analysis, writing (original draft), visualization; SC: formal analysis, screening and full-text assessment, writing (original draft), tables; CA: methodology, writing (editing); SA: screening and full-text assessment, quality assessment, tables, writing (original draft); ZBE: screening and full-text assessment, quality assessment, tables; NIG: screening and full-text assessment, quality assessment, tables; \u0130G: screening and full-text assessment, quality assessment, tables; CS: conceptualization, validation, methodology, writing (editing). AC: conceptualization, validation, writing (editing). All authors have seen and approved the final version of the manuscript; MA: conceptualization, validation, methodology, writing (editing). All authors have seen and approved the final version of the manuscript.","order":8,"name":"Ethics","label":"Authors\u2019 Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}